drugset / Trial / NCT02500316

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

NCT02500316

Phase 2 Completed 48 enrolled OPKO Health, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Protocol CP-4-004-OLE (Open Label Extension) is designed as a long-term, open-label extension using single patient use, multi-dose, disposable pre-filled pen.

Timeline

Start
2014-02
Primary completion
2023-11
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatrogon Protein / enzyme biologic 20 mg/ml Other
Subject Somatrogon Protein / enzyme biologic 50 mg/ml Other

Indications